Experience with Dopamine Agonists in the Treatment of Prolactinomas.

Q3 Medicine
Acta Medica Lituanica Pub Date : 2022-01-01 Epub Date: 2022-06-29 DOI:10.15388/Amed.2022.29.2.15
Nadiya Ye Barabash, Tetiana M Tykhonova
{"title":"Experience with Dopamine Agonists in the Treatment of Prolactinomas.","authors":"Nadiya Ye Barabash,&nbsp;Tetiana M Tykhonova","doi":"10.15388/Amed.2022.29.2.15","DOIUrl":null,"url":null,"abstract":"<p><p>The article is devoted to the conservative treatment of hyperprolactinemia of tumor origin. Cabergoline is considered as an effective treatment not only for microadenomas but also for large pituitary tumors which is illustrated by the clinical case of the patient P. The most important effects of cabergoline demonstrated in this clinical case are reduction in the size of the adenoma from macro to micro, reverse development of chiasmal syndrome with restoration of visual functions, achievement and maintenance of the target level of prolactin. Besides the article focused on the possible development of primary and secondary resistance to dopamine analogues. One of such difficult clinical scenarios is illustrated by the clinical case of patient M., who was treated with different dopamine analogues with the development of secondary dopamine resistance. Along with described in literature possible mechanisms for its development in our patient we also suggest the role of prolonged inadequate therapy with dopamine agonists, when the dose of the drug was not properly adjusted, despite not reaching the target prolactin level. The literature considers several ways of optimization of treatment in resistant patients but despite of this fact it remains one of unresolved problems in the management of patients with hyperprolactinemia.</p>","PeriodicalId":34365,"journal":{"name":"Acta Medica Lituanica","volume":"29 2","pages":"304-310"},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9799005/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Medica Lituanica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15388/Amed.2022.29.2.15","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/6/29 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

The article is devoted to the conservative treatment of hyperprolactinemia of tumor origin. Cabergoline is considered as an effective treatment not only for microadenomas but also for large pituitary tumors which is illustrated by the clinical case of the patient P. The most important effects of cabergoline demonstrated in this clinical case are reduction in the size of the adenoma from macro to micro, reverse development of chiasmal syndrome with restoration of visual functions, achievement and maintenance of the target level of prolactin. Besides the article focused on the possible development of primary and secondary resistance to dopamine analogues. One of such difficult clinical scenarios is illustrated by the clinical case of patient M., who was treated with different dopamine analogues with the development of secondary dopamine resistance. Along with described in literature possible mechanisms for its development in our patient we also suggest the role of prolonged inadequate therapy with dopamine agonists, when the dose of the drug was not properly adjusted, despite not reaching the target prolactin level. The literature considers several ways of optimization of treatment in resistant patients but despite of this fact it remains one of unresolved problems in the management of patients with hyperprolactinemia.

Abstract Image

多巴胺激动剂治疗泌乳素瘤的经验。
本文致力于肿瘤源性高泌乳素血症的保守治疗。卡麦角林被认为不仅是治疗微腺瘤的有效方法,而且是治疗大型垂体瘤的有效方法。患者P的临床病例说明了这一点。在该临床病例中证明的卡麦角碱最重要的作用是从宏观到微观缩小腺瘤的大小,逆转交叉综合征的发展并恢复视觉功能,泌乳素目标水平的实现和维持。此外,本文还重点讨论了对多巴胺类似物的一级和二级耐药性的可能发展。患者M的临床案例说明了这种困难的临床场景之一,他接受了不同的多巴胺类似物治疗,并出现了继发性多巴胺耐药性。除了文献中描述的其在我们患者中发展的可能机制外,我们还提出了多巴胺激动剂长期不足治疗的作用,当药物剂量没有得到适当调整时,尽管没有达到目标催乳素水平。文献考虑了几种优化耐药患者治疗的方法,但尽管如此,这仍然是高泌乳素血症患者管理中尚未解决的问题之一。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Acta Medica Lituanica
Acta Medica Lituanica Medicine-General Medicine
CiteScore
0.70
自引率
0.00%
发文量
33
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信